Skip to content

Author

José Pablo Miramontes González

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.

Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).

José Pablo Miramontes González · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.